The short version of Albumin binding fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-20 and is reviewed periodically as new material appears.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Second, Australian public enterprises, state laws, and private corporations have frequently created worker directors, and voting rights for employees. In 1952 a trade union representative was included on the board of the new Electricity Commission of New South Wales. Other state electricity authorities did the same. The NSW State Dockyard and the railways included worker directors. There was also a worker director on the board of the South Australian Meat Corporation from 1972. In 1984 there were 19 different state corporations with worker directors. Under the Public Service Reform Act 1984, section 12 required that each government department "in consultation with relevant staff organizations... cause to be developed an industrial democracy plan for the Department". By 1995, 13% of all workplaces surveyed had employee representatives on boards, most common in education, health, and communications. Federally there were worker directors at statutory corporations including the ABC, Qantas, Telstra, Australia Post and the Reserve Bank during the ALP Government from 1983 to 1996. There were also requirements for employee-elected directors at major universities, such as the University of Melbourne, but not yet requirements for a majority to be elected by staff as is found in institutions such as Cambridge and Oxford.
Although there are clinical situations where transfusion with red blood cells is the only clinically appropriate option, clinicians look at whether alternatives are feasible. This can be due to several reasons, such as patient safety, economic burden or scarcity of blood. Guidelines recommend blood transfusions should be reserved for patients with or at risk of cardiovascular instability due to the degree of their anaemia. In stable patients with iron deficiency anemia, oral or parenteral iron is recommended. Non-blood volume expanders are available for cases where only volume restoration is required, but a substance with oxygen-carrying capacity would help doctors and surgeons avoid the risks of disease transmission and immune suppression, address the chronic blood donor shortage, and address the concerns of Jehovah's Witnesses and others who have religious objections to receiving transfused blood. The research in this area is ongoing. A number of blood substitutes have been explored, but thus far they all have serious limitations, and as of 2023 no blood substitutes have been approved for use in transfusions, however the European Union, Russia, South Africa and Mexico have all approved the use of blood substitutes in other clinical settings. Most attempts to find a suitable alternative to blood thus far have concentrated on cell-free hemoglobin solutions. Blood substitutes could make transfusions more readily available in emergency medicine and in pre-hospital EMS care.
==== New Zealand ==== In February 2022, Pharmac recommended, with medium priority, funding for people aged 12 years and over. In December 2022, Pharmac announced it had reached a provisional agreement with Vertex funding Trikafta starting on 1 April 2023 for patients aged six or above.
Davidson, Alan (1979). North Atlantic Seafood. ISBN 0-670-51524-8. Kurlansky, Mark (1997). Cod: A Biography of the Fish That Changed the World. New York: Walker. ISBN 0-8027-1326-2. Sanjuán, Gloria (2009). La Cocina del Bacalao. Madrid: Libro Hobby. ISBN 978-84-9736-242-9.
Sources: en.wikipedia.org
The Gaza Strip, now a part of the State of Palestine, has previously been under Ottoman, British, and Egyptian control. Israel directly occupied the entirety of Gaza from 1967 to 1993, when the Palestinian Authority assumed civil control of most of the region. In 2005, Israel disengaged from the Gaza Strip, the same year the militant group Hamas won parliamentary elections in the region. Decades-long US diplomacy on Israel and the Palestinians have not produced successful resolutions in the conflict. The Gaza Strip has seen a major scale of destruction since the beginning of the Gaza war in October 2023. Civilians who were internally displaced have been able to return to their homes since the ceasefire which began on 15 January 2025. The cost of rebuilding Gaza has been estimated to be in the tens of billions of dollars. Calls to displace Palestinians from Gaza mirror demands made by those in the Israeli far-right who have often called for ethnically cleansing Palestinian land to open it up to foreign settlement.
==== Late onset ==== Late-onset Alzheimer's is about 70% heritable. Most cases of Alzheimer's are not familial, and so they are termed sporadic Alzheimer's disease. Of the cases of sporadic Alzheimer's disease, most are classified as late onset where they are developed after the age of 65 years. The strongest genetic risk factor for sporadic Alzheimer's disease is APOEε4. APOEε4 is one of the three major alleles of apolipoprotein E (APOE). APOE plays a major role in lipid-binding proteins in lipoprotein particles and the ε4 allele disrupts this function. Between 40% and 80% of people with Alzheimer's disease possess at least one APOEε4 allele. The APOEε4 allele increases the risk of the disease by three times in heterozygotes and by 15 times in homozygotes. Like many human diseases, environmental effects and genetic modifiers result in incomplete penetrance. For example, Nigerian Yoruba people do not show the relationship between the dose of APOEε4 and incidence or age-of-onset for Alzheimer's disease seen in other human populations.
amyloid protein The hypothesis that beta amyloid protein is key to IBM has been supported in a mouse model using an Aβ vaccine that was found to be effective against inclusion body myositis in mouse models. Although this vaccine is likely, not safe for human use, it still shows that attacking Aβ has efficacy in mice against IBM. Following up on earlier leads, the Greenberg group report finding that the protein TDP-43 is a very prominent and highly sensitive and specific feature of IBM. This protein is normally found within the nucleus but in IBM is found in the cytoplasm of the cell. This important advance should help develop a new screening technique for IBM and may provide clues in terms of a therapeutic approach
government considered several options to move Noriega out of the drug trafficking business, including assassinating him, and linking him to a fictional plot against Torrijos. Though no assassination attempt was made, the other ploys may have been tried in the early 1970s, according to Dinges. Dinges wrote that beginning in 1972 the U.S. relaxed its efforts at trapping individuals involved with smuggling within the Panama government, possibly as a result of an agreement between Torrijos and U.S. President Richard Nixon. During the early 1970s, Noriega's relationship with the U.S. intelligence services was regularized. The Central Intelligence Agency (CIA) placed him on its payroll in 1971, while he held his position as head of Panamanian intelligence; he had previously been paid by U.S. intelligence services on a case-by-case basis. Regular payments to him were stopped under the Carter administration, before being resumed and later stopped again under the administration of Ronald Reagan. The CIA valued him as an asset because he was willing to provide information about the Cuban government and later about the Sandinista government in Nicaragua. Noriega also served as the U.S. emissary to Cuba during negotiations following the Johnny Express incident in December 1971. Noriega was given access to CIA contingency funds, which he was supposed to use to improve his intelligence programs, but which he could spend with little accountability. The contingency funds were as high as US$100,000 in some years. The CIA was aware that Noriega was selling intelligence on the U.S.
Bain de Soleil was an American brand of sunscreen that was produced by Bayer. The brand was known for low-SPF products that were typically marketed to women seeking skin tanning. It was affiliated with the Coppertone brand. The name Bain de Soleil is French for "sun bathing." The brand used the slogan "Welcome to a place more colorful." In the 1970s and 1980s, the brand used the slogan (especially featured in television commercials) "Bain de Soleil, for the St. Tropez tan." The brand was discontinued in December 2019.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.